|
CoronaVac
|
Sinovac Research and Development Co., Ltd
|
Inactivated virus
|
Phase 4
|
|
BBIBP-CorV
|
Sinopharm
|
Inactivated virus
|
Phase 4
|
|
ChAdOx1-S - (AZD1222)
|
AstraZeneca & University of Oxford
|
Viral vector
|
Phase 4
|
|
Ad26.COV2.S
|
Janssen Pharmaceutical
|
Viral vector
|
Phase 4
|
|
mRNA-1273
|
Moderna & National Institute of Allergy and Infectious Diseases
(NIAID)
|
RNA-based
|
Phase 4
|
|
BNT162b2 also known as ”Comirnaty”
|
Pfizer/BioNTech & Fosun Pharma
|
RNA-based
|
Phase 4
|
|
MVC-COV1901
|
Medigen Vaccine Biologics, Dynavax & National Institute of Allergy and
Infectious Diseases (NIAID)
|
Protein-sub unit
|
Phase 4
|
|
Recombinant COVID-19 vaccine for Inhalation (Ad5-nCoV-IH)
|
CanSino Biological Inc./Beijing Institute of Biotechnology
|
Viral vector
|
Phase 3
|
|
Gam-COVID-Vac Adeno-based
|
Gamaleya Research Institute; Health Ministry of the Russian
Federation
|
Viral vector
|
Phase 3
|
|
SARS-CoV-2 rS/Matrix M1-Adjuvant
|
Novavax
|
Protein- subunit
|
Phase 3
|
|
Recombinant SARS-CoV-2 vaccine
|
Anhui Zhifei Longcom Biopharmaceutical & Institute of Microbiology,
Chinese Academy of Sciences
|
Protein- subunit
|
Phase 3
|
|
CVnCoV Vaccine
|
CureVac AG
|
RNA-based
|
Phase 3
|
|
SARS-CoV-2 vaccine
|
Institute of Medical Biology & Chinese Academy of Medical
Sciences
|
Inactivated virus
|
Phase 3
|
|
QazCovid-in®
|
Research Institute for Biological Safety Problems, Rep of
Kazakhstan
|
Inactivated virus
|
Phase 3
|
|
nCov vaccine
|
Zydus Cadila
|
DNA-based
|
Phase 3
|
|
BBV152 vaccine
|
Bharat Biotech International Limited
|
Inactivated virus
|
Phase 3
|
|
VAT00008
|
Sanofi Pasteur & GSK
|
Protein-sub unit
|
Phase 3
|
|
Inactivated SARS-CoV-2 vaccine
|
Shenzhen Kangtai Biological Products Co., Ltd.
|
Inactivated vaccine
|
Phase 3
|
|
CpG 1018/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein
Subunit Vaccine (SCB-2019)
|
Clover Biopharmaceuticals Inc./Dynavax
|
Protein-sub unit
|
Phase 3
|
|
COVAX-19®
|
Vaxine Pty Ltd./CinnaGen Co
|
Protein-sub unit
|
Phase 3
|
|
FINLAY-FR-2 anti-SARS-CoV-2 Vaccine
|
Instituto Finlay de Vacunas
|
Protein-sub unit
|
Phase 3
|
|
EpiVacCorona
|
Federal Budgetary Research Institution State Research Center of Virology
and Biotechnology ”Vector”
|
Protein-sub unit
|
Phase 3
|
|
ARCoV
|
Academy of Military Science (AMS), Walvax Biotechnology, and Suzhou
Abogen Biosciences
|
RNA-based
|
Phase 3
|
|
Coronavirus-Like Particle COVID-19 (CoVLP)
|
Medicago Inc.
|
Virus like particle
|
Phase 3
|
|
COVI-VAC
|
Codagenix/Serum Institute of India
|
Live attenuated
|
Phase 3
|
|
CIGB-66
|
The Center for Genetic Engineering and Biotechnology (CIGB)
|
Protein-sub unit
|
Phase 3
|
|
VLA2001
|
Valneva, National Institute for Health Research, United Kingdom
|
Inactivated vaccine
|
Phase 3
|
|
BECOV2
|
Biological E. Limited
|
Protein-sub unit
|
Phase 3
|
|
Nanocovax
|
Nanogen Pharmaceutical Biotechnology
|
Protein-sub unit
|
Phase 3
|
|
TURKOVAC
|
Erciyes University and the Health Institutes of Turkey (TUSEB)
|
Inactivated virus
|
Phase 3
|
|
GBP510
|
SK Bioscience Co., Ltd., and CEPI
|
Protein-sub unit
|
Phase 3
|
|
Razi Cov Pars
|
Razi Vaccine and Serum Research Institute
|
Protein-sub unit
|
Phase 3
|
|
Noora vaccine
|
Bagheiat-Allah University of Medical Sciences/AmitisGen
|
Protein-sub unit
|
Phase 3
|
|
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
|
Livzon Pharmaceutical
|
Protein-sub unit
|
Phase 3
|
|
ARCT-154
|
Arcturus Therapeutics, Inc.
|
RNA-based
|
Phase 3
|